Tilray, Inc. - Class 2 (TLRY): Price and Financial Metrics

Tilray, Inc. - Class 2 (TLRY): $12.01

-0.02 (-0.17%)

POWR Rating

Component Grades














  • Growth is the dimension where TLRY ranks best; there it ranks ahead of 61.56% of US stocks.
  • The strongest trend for TLRY is in Momentum, which has been heading up over the past 31 weeks.
  • TLRY ranks lowest in Sentiment; there it ranks in the 4th percentile.

TLRY Stock Summary

  • Tilray Inc's stock had its IPO on July 19, 2018, making it an older stock than merely 7.98% of US equities in our set.
  • TLRY's price/sales ratio is 34.7; that's higher than the P/S ratio of 93.12% of US stocks.
  • The volatility of Tilray Inc's share price is greater than that of 95.73% US stocks with at least 200 days of trading history.
  • Stocks that are quantitatively similar to TLRY, based on their financial statements, market capitalization, and price volatility, are BIOL, NOV, FOLD, OTRK, and PGEN.
  • TLRY's SEC filings can be seen here. And to visit Tilray Inc's official web site, go to www.tilray.com.

TLRY Valuation Summary

  • TLRY's price/sales ratio is 29.5; this is 719.44% higher than that of the median Healthcare stock.
  • TLRY's price/earnings ratio has moved up 76.4 over the prior 37 months.
  • Over the past 37 months, TLRY's EV/EBIT ratio has gone up 84.7.

Below are key valuation metrics over time for TLRY.

Stock Date P/S P/B P/E EV/EBIT
TLRY 2021-06-09 46.4 17.7 -22.4 -23.8
TLRY 2020-08-05 5.2 5.3 -2.1 -3.0
TLRY 2019-11-21 16.6 5.4 -17.1 -24.3
TLRY 2019-03-21 233.2 34.8 -288.4 -307.2
TLRY 2019-03-01 263.9 39.4 -326.5 -348.2
TLRY 2018-09-28 476.6 379.7 -589.6 -637.7

TLRY Price Target

For more insight on analysts targets of TLRY, see our TLRY price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $18.38 Average Broker Recommendation 1.86 (Hold)

TLRY Stock Price Chart Interactive Chart >

Price chart for TLRY

TLRY Price/Volume Stats

Current price $12.01 52-week high $67.00
Prev. close $12.03 52-week low $4.41
Day low $11.90 Volume 9,315,900
Day high $12.24 Avg. volume 28,773,455
50-day MA $13.86 Dividend yield N/A
200-day MA $17.41 Market Cap 5.37B

Tilray, Inc. - Class 2 (TLRY) Company Bio

Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. was founded in 2018 and is based in Nanaimo, Canada.

TLRY Latest News Stream

Event/Time News Detail
Loading, please wait...

TLRY Latest Social Stream

Loading social stream, please wait...

View Full TLRY Social Stream

Latest TLRY News From Around the Web

Below are the latest news stories about Tilray Inc that investors may wish to consider to help them evaluate TLRY as an investment opportunity.

Is Tilray Stock A Buy After Key Shareholder Vote?

Canadian pot producer Tilray in August said it had invested in U.S. cannabis retailer MedMen. Should you buy TLRY stock now?

Yahoo | September 13, 2021

Cannabis Sector Weekly Roundup

Key Points • Tilray, Inc. Announces Shareholders Approval to Boost the Authorized Share-Count • The National Hemp Association (NHA) Asks Congress To Budget $1 Billion To Support Industrial Innovations and Research on the Cannabis Crop. • Top Federal National Credit Union Administration (NCUA) Regulator Sharply Criticizes Congress for Failing to Reform Marijuana Laws. • Greenlane […] The post Cannabis Sector Weekly Roundup appeared first on Market Exclusive.

Yahoo | September 13, 2021

Tilray Stockholders Approve Proposal to Increase Authorized Shares at Special Meeting

NEW YORK & LEAMINGTON, Ontario--(BUSINESS WIRE)--Tilray, Inc. (Tilray or the Company) (NASDAQ | TSX: TLRY), a leading global cannabis-lifestyle and consumer packaged goods company, today announced that stockholders holding more than a majority of its issued and outstanding shares of common stock have approved an increase in the number of authorized shares of its common stock. Irwin D. Simon, Chairman and CEO, Tilray said: We brought together Tilray and Aphria less than five months ago with

Business Wire | September 10, 2021

The Week In Cannabis: Tilray, BMW, Teen Use, The Valens Co, Flora Growth, Italy And More

Below is a recap of the main news related to the cannabis industry and markets for the week of September 6, 2021. Contents Tilray BMW Commits To Hemp And Recycling Italy No Relation Between Marijuana Legalization And Increased Use Among Teenagers Markets M&A Financings Earnings Reports Poke A Bowl AUDACIOUS Teams Up With Professional Bull Riders On CBD Products The Valens Co Flora Growth Michigan Other News Top Stories Of The Week Tilray Shares of cannabis giant Tilray Inc. (NASDAQ: TLRY) (TSX:

Yahoo | September 10, 2021

Tilray Stockholders Approve Increase In Number Of Shares To Help Drive $4B In Revenue, Stock Trades Down

Shares of cannabis giant Tilray Inc. (NASDAQ: TLRY) (TSX: TLRY) are trading down on Friday afternoon, after the company reported that its stockholders have approved an increase in the number of authorized shares of its common stock. As such, the cannabis company said that with additional authorized shares, it can accelerate its progress toward its goal of delivering $4 billion in revenue, a goal Tilray CEO Irwin Simon told Benzinga it intended to achieve by the end of fiscal 2024. The company is

Yahoo | September 10, 2021

Read More 'TLRY' Stories Here

TLRY Price Returns

1-mo -9.43%
3-mo -28.98%
6-mo -52.62%
1-year 121.18%
3-year -92.25%
5-year N/A
YTD 45.40%
2020 -51.78%
2019 -75.72%
2018 N/A
2017 N/A
2016 N/A

Continue Researching TLRY

Want to see what other sources are saying about Tilray Inc's financials and stock price? Try the links below:

Tilray Inc (TLRY) Stock Price | Nasdaq
Tilray Inc (TLRY) Stock Quote, History and News - Yahoo Finance
Tilray Inc (TLRY) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.8213 seconds.